Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.62 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.62 |
| ▸ | DGAT1 | O75907 | 8/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | CNR2 | P34972 | 2/20 | 0.58 |
| ▸ | STAT3 | P40763 | 1/20 | 0.57 |
| ▸ | PPARG | P37231 | 1/20 | 0.56 |
| ▸ | MTOR | P42345 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL774442 | 0.89 | RAB9A (0.65) | MAPTSMN1; SMN2LMNAHTTRAB9A | |
| SCHEMBL1140406 | 0.88 | MAPT (0.62) | MAPTSMN1; SMN2LMNAHTTRAB9A | |
| SCHEMBL1140439 | 0.88 | MAPT (0.62) | MAPTSMN1; SMN2LMNAHTTRAB9A | |
| SCHEMBL1140259 | 0.85 | MAPT (0.58) | MAPTSMN1; SMN2LMNAHTTRAB9A | |
| SCHEMBL1140823 | 0.85 | MAPT (0.58) | MAPTSMN1; SMN2LMNAHTTRAB9A | |
| SCHEMBL3919958 | 0.82 | MAPT (0.66) | MAPTSMN1; SMN2LMNAHTTKCNQ3 | |
| SCHEMBL2169030 | 0.81 | MAPT (0.78) | MAPTSMN1; SMN2LMNAHTTRAB9A | |
| SCHEMBL3990821 | 0.81 | RAB9A (0.62) | MAPTSMN1; SMN2LMNAHTTRAB9A | |
| SCHEMBL774698 | 0.81 | KCNQ3 (0.77) | KCNQ3KCNQ2 | |
| SCHEMBL12323377 | 0.79 | MAPT (0.65) | MAPTSMN1; SMN2LMNAHTTKCNQ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071513-A1 | Compositions and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2012-03-22 | — | — | US | claimed |
| US-20110178087-A1 | Compositions and Their Use as Anti-Tumor Agents | Compass Pharmaceuticals LLC. (US) | 2011-07-21 | — | — | US | claimed |
| EP-1802606-B1 | ARYLCARBOXAMIDES AND THEIR USE AS ANTI-TUMOR AGENTS | COMPASS PHARMACEUTICALS LLC (US) | 2011-03-16 | — | — | EP | claimed |
| US-20090018145-A1 | Compositions and their use as anti-tumor agents | COMPASS PHARMACEUTICALS LLC (US) | 2009-01-15 | — | — | US | claimed |
| US-20120071513-A1 | Compositions and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2012-03-22 | — | — | US | disclosed |
| US-20110178087-A1 | Compositions and Their Use as Anti-Tumor Agents | Compass Pharmaceuticals LLC. (US) | 2011-07-21 | — | — | US | disclosed |
| EP-1802606-B1 | ARYLCARBOXAMIDES AND THEIR USE AS ANTI-TUMOR AGENTS | COMPASS PHARMACEUTICALS LLC (US) | 2011-03-16 | — | — | EP | disclosed |
| US-20090018145-A1 | Compositions and their use as anti-tumor agents | COMPASS PHARMACEUTICALS LLC (US) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071513-A1 | Compositions and Their Use as Anti-Tumor Agents | TP53, VHL, RB1 | MAPT 2839/4885SMN1; SMN2 206/4885LMNA 751/4885 |
| US-20110178087-A1 | Compositions and Their Use as Anti-Tumor Agents | TP53, VHL, RB1 | MAPT 2839/4885SMN1; SMN2 206/4885LMNA 751/4885 |
| US-20090018145-A1 | Compositions and their use as anti-tumor agents | TP53, VHL, RB1 | MAPT 3315/4885SMN1; SMN2 214/4885LMNA 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.